Sign in
4

Changes in Ownership

Beam Therapeutics Inc. Filed Acc 0001193125-26-292526

CEO sold 50,000 shares at an average $34.90 ($1,745,037)

  • CEO acquired 50,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Evans John M. CEO 2026-06-29 Option exercise 10b5-1 +18,663 $0.67 $12,504 1,065,868 D: show line 1 in the form
Evans John M. CEO 2026-06-29 Option exercise 10b5-1 +6,337 $1.03 $6,527 1,072,205 D: show line 2 in the form
Evans John M. CEO 2026-06-29 Sale 10b5-1 −13,421 $35.13 $471,528 1,058,784 D: show line 3 in the form
Evans John M. CEO 2026-06-29 Sale 10b5-1 −11,579 $35.91 $415,824 1,047,205 D: show line 4 in the form
Evans John M. CEO 2026-06-30 Option exercise 10b5-1 +25,000 $1.03 $25,750 1,072,205 D: show line 5 in the form
Evans John M. CEO 2026-06-30 Sale 10b5-1 −23,100 $34.26 $791,482 1,049,105 D: show line 6 in the form
Evans John M. CEO 2026-06-30 Sale 10b5-1 −1,900 $34.84 $66,203 1,047,205 D: show line 7 in the form
Open-market sales · 50,000 sh · avg $34.90 · $1,745,037

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Evans John M. CEO 2026-06-29 Option exercise · Stock Option (Right to Buy) 10b5-1 −18,663 9 D: show line 8 in the form
Evans John M. CEO 2026-06-29 Option exercise · Stock Option (Right to Buy) 10b5-1 −6,337 230,804 D: show line 9 in the form
Evans John M. CEO 2026-06-30 Option exercise · Stock Option (Right to Buy) 10b5-1 −25,000 205,804 D: show line 10 in the form
Loading xslF345X06/ownership.xml…